These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 2343042)

  • 1. Effect of a new cholecystokinin receptor antagonist loxiglumide on acute pancreatitis in two experimental animal models.
    Tani S; Okabayashi Y; Nakamura T; Fujii M; Itoh H; Otsuki M
    Pancreas; 1990 May; 5(3):284-90. PubMed ID: 2343042
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CCK administration after CCK receptor blockade accelerates recovery from cerulein-induced acute pancreatitis in rats.
    Nakano S; Kihara Y; Otsuki M
    Pancreas; 1998 Mar; 16(2):169-75. PubMed ID: 9510141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of a new cholecystokinin receptor antagonist CR 1392 on caerulein-induced acute pancreatitis in rats.
    Otsuki M; Tani S; Okabayshi Y; Nakamura T; Fujii M; Fujisawa T; Baba S; Itoh H
    Pancreas; 1989; 4(2):237-43. PubMed ID: 2474165
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of the cholecystokinin receptor antagonist loxiglumide on pancreatic exocrine function in rats after acute pancreatitis.
    Nakano S; Tachibana I; Otsuki M
    Pancreas; 1995 Apr; 10(3):287-94. PubMed ID: 7542770
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fasting prevents acute pancreatitis induced by cerulein in rats.
    Otsuki M; Tani S; Okabayashi Y; Fujii M; Nakamura T; Fujisawa T; Koide M; Itoh H
    Dig Dis Sci; 1990 Jul; 35(7):840-8. PubMed ID: 2364838
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of loxiglumide on experimental acute pancreatitis in comparison with gabexate mesilate.
    Kimura K; Tominaga K; Fujii M; Saito T; Kasai H
    Arzneimittelforschung; 1998 Jan; 48(1):65-9. PubMed ID: 9522035
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Involvement of endogenous cholecystokinin in the development of acute pancreatitis induced by closed duodenal loop.
    Tani S; Itoh H; Koide M; Okabayashi Y; Otsuki M
    Pancreas; 1993 Jan; 8(1):109-15. PubMed ID: 7678322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protective effect of CR 1409 (cholecystokinin antagonist) on experimental pancreatitis in rats and mice.
    Makovec F; Bani M; Cereda R; Chistè R; Revel L; Rovati LC; Setnikar I; Rovati LA
    Peptides; 1986; 7(6):1159-64. PubMed ID: 3104890
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Experimental acute pancreatitis induced by excessive doses of caerulein in rats; protective and therapeutic effects of trypsin inhibitor urinastatin and CCK receptor antagonist CR1392.
    Tani S
    Kobe J Med Sci; 1988 Apr; 34(2):93-112. PubMed ID: 3216603
    [No Abstract]   [Full Text] [Related]  

  • 10. Asperlicin, a nonpeptidal cholecystokinin receptor antagonist, attenuates sodium taurocholate-induced acute pancreatitis in rats.
    Wisner JR; Renner IG
    Pancreas; 1988; 3(2):174-9. PubMed ID: 2453874
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic effects of loxiglumide on experimental acute pancreatitis using various models.
    Satake K; Kimura K; Saito T
    Digestion; 1999; 60 Suppl 1():64-8. PubMed ID: 10026435
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment with cholecystokinin receptor antagonist loxiglumide enhances insulin response to intravenous glucose stimulation in postpancreatitic rats.
    Otsuki M; Nakano S; Tachibana I
    Regul Pept; 1994 Jul; 52(2):85-95. PubMed ID: 7972939
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of T-0632, a cholecystokininA receptor antagonist, on experimental acute pancreatitis.
    Taniguchi H; Yomota E; Kume E; Shikano T; Endo T; Nagasaki M
    Jpn J Pharmacol; 1997 Feb; 73(2):105-12. PubMed ID: 9074944
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of MCI-727 on pancreatic exocrine secretion and acute pancreatitis in two experimental rat models.
    Tachibana I; Watanabe N; Shirohara H; Akiyama T; Nakano S; Otsuki M
    Pancreas; 1996 Mar; 12(2):165-72. PubMed ID: 8720664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of the CCK-antagonist loxiglumide on bile-induced experimental pancreatitis.
    Leonhardt U; Seidensticker F; Fussek M; Stöckmann F; Creutzfeldt W
    Int J Pancreatol; 1991 Sep; 10(1):73-80. PubMed ID: 1757732
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Loxiglumide. A new proglumide analog with potent cholecystokinin antagonistic activity in the rat pancreas.
    Otsuki M; Fujii M; Nakamura T; Okabayashi Y; Tani S; Fujisawa T; Koide M; Baba S
    Dig Dis Sci; 1989 Jun; 34(6):857-64. PubMed ID: 2470557
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loxiglumide protects against experimental pancreatitis.
    Setnikar I; Bani M; Cereda R; Chisté R; Makovec F; Pacini MA; Revel L
    Arzneimittelforschung; 1987 Oct; 37(10):1172-4. PubMed ID: 3435590
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Caerulein-induced acute necrotizing pancreatitis in mice: protective effects of proglumide, benzotript, and secretin.
    Niederau C; Ferrell LD; Grendell JH
    Gastroenterology; 1985 May; 88(5 Pt 1):1192-204. PubMed ID: 2984080
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical evaluation of oral administration of a cholecystokinin-A receptor antagonist (loxiglumide) to patients with acute, painful attacks of chronic pancreatitis: a multicenter dose-response study in Japan.
    Shiratori K; Takeuchi T; Satake K; Matsuno S;
    Pancreas; 2002 Jul; 25(1):e1-5. PubMed ID: 12131781
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of tetraprenylacetone on pancreatic exocrine secretion and acute pancreatitis in two experimental models in rats.
    Tachibana I; Watanabe N; Shirohara H; Akiyama T; Nanano S; Otsuki M
    Int J Pancreatol; 1995 Apr; 17(2):147-54. PubMed ID: 7542690
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.